Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB08 vs Norditropin in Pediatric GHD
NCT07126288Phase 3Not yet recruiting
- Sponsor
- Kexing Biopharm
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of GB08 in growth hormone deficiency (GHD), sponsored by Kexing Biopharm. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
GB08
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07126288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126288.